The Global Enteric Disease Testing Market was valued at USD 3.87 billion in 2023 and is anticipated to grow with a healthy growth rate of 3.3% over the forecast period 2024-2032. Enteric diseases, which affect the gastrointestinal tract, are caused by various pathogens such as bacteria, viruses, and parasites. These diseases include Clostridium difficile (C. difficile), campylobacteriosis, cholera, Escherichia coli (E. coli), Helicobacter pylori (H. pylori), salmonellosis, shigellosis, norovirus, rotavirus, amebiasis, cryptosporidiosis, and giardiasis. Diagnostic tests for these diseases involve analyzing samples of stool, blood, or other bodily fluids to identify the specific pathogens responsible.

The market for enteric disease testing is witnessing substantial growth driven by the increasing demand for convenience foods, which has led to a higher prevalence of enteric diseases. Busy lifestyles have prompted consumers to shift from traditional food products to packaged and ready-to-eat meals, which often contain additives and preservatives that can lead to contamination. This shift has heightened the need for enteric disease testing, as the risk of contamination in packaged foods and beverages is higher. Despite the positive market drivers, certain challenges hinder market growth. The lack of stringent regulations governing pathogen testing in developing economies poses a significant restraint. The food industry in these regions is fragmented and dominated by small, unorganized players who may not adhere to proper food testing practices. Additionally, the high cost associated with testing food and water, particularly with automated instruments and advanced technologies, presents a barrier to widespread adoption. Also, technological innovations in the enteric disease testing industry are creating lucrative opportunities for market expansion. Advancements in supply chain technologies have revolutionized the business, reducing lead times and overall testing costs. Improved software, network connectivity, and advanced sensors are gaining traction, making testing more efficient and affordable.

Europe dominated the market with the largest revenue share in 2023, driven by its large geriatric population, particularly in Germany. The aging population is more susceptible to enteric diseases due to decreased immunity levels, increasing the demand for rapid diagnostic techniques such as point-of-care diagnostic devices. Key manufacturers like Roche and Bio-Rad are enhancing their operations in Germany, further boosting the market.

Major market players included in this report are:
Abbott
BD
Biomerica
BIOMERIEUX
Bio-Rad Laboratories, Inc.
Cepheid
Coris BioConcept
DiaSorin S.p.A.
Meridian Bioscience
Quest Diagnostics Incorporated
The detailed segments and sub-segment of the market are explained below:
By Disease Type:
Bacterial Enteric Disease
Viral Enteric Disease
Parasitic Enteric Disease
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.